The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

President Trump’s executive order to lower drug prices through cross-agency action left pharma leaders scrambling to make ...

Medicare seeks public comments as the agency plans to list up to 15 additional drugs selected for the third round of pricing ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...

AHA comments on the Centers for Medicare & Medicaid Services information collection request regarding the Medicare Transaction Facilitator (MTF) under the Medicare drug negotiation program.

The executive order was the largest action to date by the second Trump administration on prescription drug costs but experts ...